Late-breaking observational data show patients with type 2 diabetes taking JANUVIA® (sitagliptin) and metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea and metformin
(GCI Health NY) Merck, known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA® (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2014 Category: Global & Universal Source Type: news
AWARD-5: Dulaglutide Betters Sitagliptin in Type 2 DiabetesAWARD-5: Dulaglutide Betters Sitagliptin in Type 2 Diabetes
In patients with type 2 diabetes uncontrolled with metformin, adding weekly injections of dulaglutide led to better glycemic control at 1 year compared with adding oral sitagliptin, with acceptable safety. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 28, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
New York Attorney Now Accepting Januvia, Janumet, Byetta or...
Commack, New York law firm, Rudolph F.X. Migliore, P.C., is accepting cases from individuals who took the prescription medication Januvia, Janumet, Byetta or Victoza and later developed pancreatic...(PRWeb November 05, 2013)Read the full story at http://www.prweb.com/releases/2013/11/prweb11297852.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 5, 2013 Category: Pharmaceuticals Source Type: news
Gliptins: IQWiG assessed data subsequently submitted by the manufacturer
(Institute for Quality and Efficiency in Health Care) New subgroup analyses showed that two studies on sitagliptin were also relevant for the fixed combination of sitagliptin/metformin. Hints of an added benefit can now be derived. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 9, 2013 Category: Global & Universal Source Type: news
Diabetes drugs may be linked to pancreatic cancer
Conclusion
This article presents important concerns that glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors could potentially increase the risk of inflammation and cancerous changes in the pancreas.
The agencies that regulate medicines in Europe and the USA are aware of these issues, and told the BMJ that their analyses show increased reporting of pancreatic cancer among people taking these types of drugs.
However, the agencies note that it has not been established whether these drugs directly cause the adverse effects seen in the pancreas. Both agencies are reviewing emerging eviden...
Source: NHS News Feed - June 10, 2013 Category: Consumer Health News Tags: Medication Diabetes QA articles Source Type: news
Invokana Tops Januvia as Third-Line Therapy, With DrawbacksInvokana Tops Januvia as Third-Line Therapy, With Drawbacks
In patients with type 2 diabetes not controlled with metformin plus sulfonylurea, adding canagliflozin provided better glucose control than adding sitagliptin, but with increased genital infections. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 16, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Sitagliptin and exenatide associated with an increased risk of acute pancreatitis
Source: JAMA Internal Medicine
Area: News
According to a study published in JAMA Internal Medicine, treatment of type 2 diabetes mellitus with the glucagon-like peptide (GLP)-1-based therapies sitagliptin and exenatide was associated with increased odds of hospitalisation for acute pancreatitis.
A large administrative database in the United States was used to collect data for the population-based case-control study - adults with type 2 diabetes mellitus aged 18 to 64 years were identified and 1269 hospitalised cases with acute pancreatitis using a validated algorithm and 1269 control subjects matche...
Source: NeLM - News - February 26, 2013 Category: Drugs & Pharmacology Source Type: news
Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results
Dateline City:
WHITEHOUSE STATION, N.J.
2012 Full-Year Non-GAAP EPS of $3.82, Excluding Certain Items; GAAP EPS of $2.16; Fourth-Quarter Non-GAAP EPS of $0.83, Excluding Certain Items; GAAP EPS of $0.46
2012 Full-Year Worldwide Sales Were $47.3 Billion, a Decrease of 2 Percent, Including a 3 Percent Unfavorable Impact from Foreign Exchange; Fourth-Quarter Worldwide Sales Were $11.7 Billion, a Decline of 5 Percent, Including a 2 Percent Unfavorable Impact...
Source: Merck.com - Corporate News - February 1, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Source Type: news
